Alex A. Adjei

Alex A. Adjei is a Consultant in Oncology, Professor of Oncology and Professor of Pharmacology at Mayo Clinic and Mayo College of Medicine, in Rochester, MN.

Dr. Adjei oversees oncology drug development as well as lung cancer research and treatment across all 3 Mayo Clinic sites, and is co-Leader of the Developmental Therapeutics program at Mayo Cancer Center.

Dr. Adjei has served on a number of U.S National Cancer Institute committees. From 2007 to 2013, he was Chair of the NIH Study Section NCRR Clinical Research Review Committee, reviewing CTSAs. From 2010 – 2014, he was a Member of the Clinical Oncology Study Section (CONC), and from 2013-2017, he was a member of NCI IRG Subcommittee A, reviewing Cancer Centers. He is currently co-chair of the Thoracic Malignancies Steering Committee of NCI. He has also served on various committees of professional societies (AACR, ASCO, ESMO, IASLC). Dr. Adjei is currently serving on the Committee on Diagnosing and Treating Adult Cancers of the U.S National Academies of Sciences, Engineering and Medicine, tasked with providing a report on this topic to the U.S government (Social Security Administration). He is the Editor-in-Chief of the Journal of Thoracic Oncology, and the inaugural Editor-in-Chief of JTO Clinical and Research Reports.

Dr. Adjei’s research is focused on experimental therapeutics and clinical drug development. He has been the principal investigator for over 70 early phase clinical trials. He has served on scientific advisory boards for a large number of pharmaceutical companies including Pfizer, Novartis, Bayer, Boehringer-Ingelheim, Merck AG, Daiichi-Sankyo, Amgen, Millenium, Onyx and Roche among others, and have served as Scientific advisor to a number of small and start-up companies such as Exelixis, Array Biopharma, Chiron, Nektar, Merrimack, Cagent, Cleveland BioLabs, Zeno Pharmaceuticals and Swiss Rockets. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He has authored 280 publications dealing primarily with preclinical pharmacology and phase 1 trials as well as novel therapies for lung cancer.